Rey G, Bounebache K, Rondet C. Causes of deaths data, linkages and big data perspectives. J Forensic Leg Med. 2018 Jul;57:37–40.
Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec;17(12):1219–24.
Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford). 2018 Jun 1;57(6):1047–55.
Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239–48.
Affret A, Severi G, Dow C, Mancini FR, Rey G, Delpierre C, et al. Socio-economic factors associated with an increase in fruit and vegetable consumption: a 12-year study in women from the E3N-EPIC study. Public Health Nutr. 2018;21(4):740–55.
Antero-Jacquemin J, Pohar-Perme M, Rey G, Toussaint J-F, Latouche A. The heart of the matter: years-saved from cardiovascular and cancer deaths in an elite athlete cohort with over a century of follow-up. Eur J Epidemiol. 2018 Jun;33(6):531–43.
Clergue F, Auroy Y, Pequignot F, Jougla E, Lienhart A, Laxenaire M-C. Evolution of the anaesthetic workload--the French experience. Best Pract Res Clin Anaesthesiol. 2002 Sep;16(3):459–73.
de Saint Maurice G, Aouba A, Pequignot F, Auroy Y, Benhamou D, Jougla E, et al. Anesthesia-related mortality. Anesthesiology. 2009 Nov;111(5):1165; author reply 1166.
Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey. Clin Infect Dis. 2009 Mar 1;48(5):633–9.
Fuhrman C, Jougla E, Uhry Z, Delmas M-C. Deaths with asthma in France, 2000-2005: a multiple-cause analysis. J Asthma. 2009 May;46(4):402–6.
Alpérovitch A, Bertrand M, Jougla E, Vidal J-S, Ducimetière P, Helmer C, et al. Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification. Eur J Epidemiol. 2009;24(11):669–75.
Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health. 2009;9:33.
Salmon-Ceron D, Rosenthal E, Lewden C, Bouteloup V, May T, Burty C, et al. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol. 2009 Apr;50(4):736–45.
Rey G, Fouillet A, Bessemoulin P, Frayssinet P, Dufour A, Jougla E, et al. Heat exposure and socio-economic vulnerability as synergistic factors in heat-wave-related mortality. Eur J Epidemiol. 2009;24(9):495–502.
Lanoy E, Lewden C, Lièvre L, Tattevin P, Boileau J, Aouba A, et al. How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates. HIV Med. 2009 Apr;10(4):236–45.
de Saint Maurice G, Pequignot F, Auroy Y, Aouba A, Benhamou D, Jougla E, et al. Patient blood management and transfusion. Anesthesiology. 2009 Aug;111(2):444–5; author reply 445-446.
Ziadé N, Jougla E, Coste J. Using vital statistics to estimate the population-level impact of osteoporotic fractures on mortality based on death certificates, with an application to France (2000-2004). BMC Public Health. 2009;9:344.
Bouvier A-M, Remontet L, Jougla E, Launoy G, Grosclaude P, Buémi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004 Oct;28(10 Pt 1):877–81.
Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004 Jul 15;101(2):317–24.